These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 27751934)
1. Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Clavert A; Peric Z; Brissot E; Malard F; Guillaume T; Delaunay J; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Milpied N; Mohty M; Chevallier P Biol Blood Marrow Transplant; 2017 Jan; 23(1):140-146. PubMed ID: 27751934 [TBL] [Abstract][Full Text] [Related]
2. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689 [TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043 [TBL] [Abstract][Full Text] [Related]
4. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083 [TBL] [Abstract][Full Text] [Related]
5. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970 [TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Abou-Mourad YR; Lau BC; Barnett MJ; Forrest DL; Hogge DE; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Lavoie JC Bone Marrow Transplant; 2010 Feb; 45(2):295-302. PubMed ID: 19597425 [TBL] [Abstract][Full Text] [Related]
7. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939 [TBL] [Abstract][Full Text] [Related]
8. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652 [TBL] [Abstract][Full Text] [Related]
9. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414 [TBL] [Abstract][Full Text] [Related]
11. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML; Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571 [TBL] [Abstract][Full Text] [Related]
12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
13. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991 [TBL] [Abstract][Full Text] [Related]
14. The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study. Valkova V; Jircikova J; Trnkova M; Steinerova K; Keslova P; Lanska M; Koristek Z; Raida L; Krejci M; Kruntoradova K; Dolezal T; Benesova K; Cetkovsky P; Trneny M Neoplasma; 2016; 63(5):743-51. PubMed ID: 27468878 [TBL] [Abstract][Full Text] [Related]
15. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680 [TBL] [Abstract][Full Text] [Related]
16. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304 [TBL] [Abstract][Full Text] [Related]
18. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI; Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879 [TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients undergoing allogeneic stem cell transplantation after reduced intensity conditioning versus myeloablative conditioning. Andersson I; Ahlberg K; Stockelberg D; Brune M; Persson LO Cancer Nurs; 2009; 32(4):325-34. PubMed ID: 19444087 [TBL] [Abstract][Full Text] [Related]